Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn

Used in the treatment of type 2 diabetes, Zomelis comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors

Premium

Representative image

Ahmedabad

2 min read Last Updated : Dec 3 2019 | 9:02 PM IST

Eris Lifesciences on Tuesday announced acquisition of the trademark Zomelis, for Vildagliptin-based formulations, and its associated trademarks from Novartis AG, Switzerland, for a consideration of $13 million (roughly Rs 93

Topics : Novartis

First Published: Dec 3 2019 | 9:00 PM IST

Explore News

Stock Market Updates World Heart Day 2023 Asian Games 2023 Kabaddi schedule Latest News Live Asian Games LIVE updates India Cricket World Cup Squad Hookah Ban in Haryana Gold-Silver Price MCX Share Price Asian Games 2023 September 30 schedule

Companies News

Air India completes acquisition of its 1st A350 aircraft through GIFT City Jalan Kalrock Consortium infuses Rs 100 crore in cash-strapped Jet Airways

Sports News

Asian Games 2023 September 30 schedule: India event timings, streaming Asian Games Day 6 Highlights: Historic shot put medal push IND tally to 33

India News

Punjab farmers continue three-day 'rail roko' agitation over MSP demand War in Ukraine pushes India to obtain more self-propelled guns to arsenal

Economy News

Adani partnership remains steadfast: IHC on Adani units' stake sale Sugar market eyes restrictions from India after lower monsoon rains

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Continue

Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn

Used in the treatment of type 2 diabetes, Zomelis comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors

Also Read

Type 2 diabetes on rise in children and teens: Here's what you must know

Price of key diabetes drug may crash as Novartis risks losing patent

Eris Lifesciences gains 6% as 3% equity changes hands via block deals

Diabetes may cause infertility in men; here are some precautionary measures

Eris Lifesciences hits record low as stock turns ex-date for share buyback

JSPL shares fall after SC defers interim order on Sarda mines case

Cybersecurity firm Lucideus raises $7 mn, doubles valuation to $100 mn

Dialysis centre chain NephroPlus eyes overseas foray; to start with Vietnam

US Court delivers judgement in favour of Eros on 'short and distort' claim

Stalemate on JSPL's Odisha iron ore continues; SC defers hearing

Explore News